Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Janet Woodcock’s Mission: Predict Adverse Events, ID Them After They Happen

Executive Summary

FDA's drug safety reforms in response to the Institute of Medicine's report include emphasizing the newly created position of chief medical officer

You may also be interested in...



FDA Reform Bill Leaves Senate With Reduced Safety Powers But Stiffer Fines

Legislation to reauthorize FDA's user fee program and expand the agency's oversight powers on drug safety has cleared the Senate with much stronger fines than originally envisioned by the sponsors, thanks to an amendment by Sen. Charles Grassley, R-Iowa

FDA Reform Bill Leaves Senate With Reduced Safety Powers But Stiffer Fines

Legislation to reauthorize FDA's user fee program and expand the agency's oversight powers on drug safety has cleared the Senate with much stronger fines than originally envisioned by the sponsors, thanks to an amendment by Sen. Charles Grassley, R-Iowa

FDA To Re-Evaluate Safety Of NMEs In Pilot Postmarket Monitoring Program

FDA will prepare safety profiles for several new molecular entities, using data from the first year of post-market experience, under a pilot program that is part of the agency's response to the Institute of Medicine's recommendations for improving drug safety in the United States

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS047997

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel